Recombinant cytokines in augmentation and immunomodulation of host defenses against Candida spp.

Medical Mycology

Volumn 42, Issue 1, 2004, Pages 1-13

  Roilides, Emmanuel ^a,b   Walsh, Thomas ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Candida spp., candidiasis; Cytokines; Host defenses; Immunomodulation

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIMICROBIAL PEPTIDE DERIVATIVE; ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR 1; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DEXAMETHASONE; FLUCONAZOLE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; LACTOFERRIN; PREDNISOLONE; RECOMBINANT CYTOKINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VORICONAZOLE;

ASPERGILLOSIS; CANDIDA; CANDIDIASIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CRITICAL ILLNESS; DRUG EFFECT; FEBRILE NEUTROPENIA; GRANULOCYTE TRANSFUSION; HOSPITAL INFECTION; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNITY; IMMUNOMODULATION; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; MONOTHERAPY; MORBIDITY; MORTALITY; MYCOSIS; NEUTROPENIA; NONHUMAN; PHAGOCYTOSIS; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; CANDIDA; CANDIDIASIS; CYTOKINES; HUMANS; RECOMBINANT PROTEINS;

CANDIDA; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0842326498     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/13693780310001631341     Document Type: Review

References (120)

1. Beck-Sague CM, Jarvis WR. The National Nosocomial Infections Surveillance System. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 1993; 167: 1247-1251.
2. Roilides E, Dignani MC, Anaissie EJ, Rex JH. The role of immunoreconstitution in the management of refractory opportunistic fungal infections. Med Mycol 1998; 36: 12-25.
3. Metcalf D, Begley CJ, Johnson GR, et al. Biologic properties in vitro of a recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1986; 67: 37-45.
4. Smith PD, Lamerson CL, Banks SM, et al. Granulocyte-macrophage colony-stimulating factor augments human monocyte fungicidal activity for Candida albicans. J Infect Dis 1990; 161: 999-1005.
5. Wang M, Friedman H, Djeu JY. Enhancement of human monocyte function against Candida albicans by the colony-stimulating factors (CSF); IL-3, granulocyte-macrophage-CSF, and macrophage-CSF. J Immunol 1989; 143: 671-677.
6. Nemunaitis J, Cox J, Meyer W, et al. Comparison of neutrophil and monocyte function by microbicidal cell-kill assay in patients with cancer receiving Granulocyte Colony-Stimulating Factor, Granulocyte-Macrophage Colony-Stimulating Factor, or no cytokine after cytotoxic chemotherapy. Amer J Clin Oncol 1998; 21: 308-312.
7. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ. Neutrophil oxidative burst in response to blastoconidia and pseudohyphae of Candida albicans: Augmentation by granulocyte colony-stimulating factor and interferon-g. J Infect Dis 1992; 166: 668-673.
8. Roilides E, Holmes A, Blake C, Pizzo PA, Walsh TJ. Effects of granulocyte colony-stimulating factor and interferon-og on antifungal activity of human polymorphonuclear neutrophils against pseudohyphae of different medically important Candida species. J Leukoc Biol 1995; 57: 651-656.
9. Roilides E, Walsh TJ, Pizzo PA, Rubin M. Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis 1991; 163: 579-583.
10. Yamamoto Y, Klein TW, Freidman H, Kimura S, Yamaguchi H. Granulocyte-colony stimulating factor potentiates anti-Candida albicans growth inhibitory activity of polymorphonuclear cells. FEMS Immunol Med Microbiol 1993; 7: 15-22.
11. Vecchiarelli A, Morani C, Baldelli F, et al. Beneficial effect of recombinant human granulocyte colony-forming factor on fungicidal activity of polymorphonuclear leukocytes from patients with AIDS. J Infect Dis 1995; 171: 1448-1454.
12. Roilides E, Farmaki E, Lyman CA. Immune reconstitution against human mycoses. In: Calderone R, Cihlar R (eds). Fungal Pathogenesis: Principles and Clinical Applications. New York: Marcel Dekker Inc, 2001: 433-460.
13. Roilides E, Pizzo PA. Modulation of host defenses by cytokines: Evolving adjuncts in prevention and treatment of serious infections in immunocompromised hosts. Clin Infect Dis 1992; 15: 508-524.
14. Karbassi A, Becker JM, Foster JS, Moore RN. Enhanced killing of Candida albicans by murine macrophages treated with macrophage colony-stimulating factor: Evidence for augmented expression of mannose receptors. J Immunol 1987; 139: 417-421.
15. Cenci E, Bartocci A, Puccetti P, et al. Macrophage colony-stimulating factor in murine candidiasis: Serum and tissue levels during infection and protective effect of exogenous administration. Infect Immun 1991; 59: 868-872.
16. Roilides E, Lyman CA, Sein T, Gonzalez C, Walsh TJ. Antifungal activity of splenic, liver and pulmonary macrophages against Candida albicans and effects of macrophage colony-stimulating factor. Med Mycol 2000; 38: 161-168.
17. Roilides E, Lyman CA, Mertins SD, et al. Ex vivo effects of macrophage colony-stimulating factor on human monocyte activity against fungal and bacterial pathogens. Cytokine 1996; 8: 42-48.
18. Khwaja A, Johnson B, Addison IE, et al. In vivo effects of macrophage colony-stimulating factor on human monocyte function. Br J Haematol 1991; 77: 25-31.
19. Roilides E, Pizzo PA. Perspectives on the use of cytokines in the management of infectious complications of cancer. Clin Infect Dis 1993; 17: S385-389.
20. Djeu JY, Blanchard DK, Halkias D, Friedman H. Growth inhibition of Candida albicans by human polymorphonuclear neutrophils: Activation by interferon-gamma and tumor necrosis factor. J Immunol 1986; 137: 2980-2984.
21. Diamond RD, Lyman CA, Wysong DR. Disparate effects of interferon-gamma and tumor necrosis factor-alpha on early neutrophil respiratory burst and fungicidal responses to Candida albicans hyphae in vitro. J Clin Invest 1991; 87: 711-720.
22. Morrison CJ, Brummer E, Isenberg RA, Stevens DA. Activation of murine polymorphonuclear neutrophils for fungicidal activity by recombinant gamma interferon. J Leukoc Biol 1987; 41: 434-440.
23. Perussia B, Kobayashi M, Rossi ME, Anegon I, Trinchieri G. Immune interferon enhances properties of human granulocytes: Role of Fc receptors and effect of lymphotoxin, tumor necrosis factor, and granulocyte-macrophage colony-stimulating factor. J Immunol 1987; 138: 765-774.
24. Ferrante A. Tumor necrosis factor alpha potentiates neutrophil antimicrobial activity: Increased fungicidal activity against Torulopsis glabrata and Candida albicans and associated increases in oxygen radical production and lysosomal enzyme release. Infect Immun 1989; 57: 2115-2122.
25. Ferrante A, Nandoskar M, Walz A, Goh DHB, Kowanko IC. Effects of tumour necrosis factor alpha and interleukin-1 alpha and beta on human neutrophil migration, respiratory burst and degranulation. Int Arch Appl Immunol 1988; 86: 82-91.
26. Atkinson YH, Marasco WA, Lopez AF, Vadas AM. Recombinant human tumor necrosis factor alpha. Regulation of N-formyl methionyl leucyl phenylalanine receptor affinity and function on human neutrophils. J Clin Invest 1988; 81: 759-765.
27. Roilides E, Kadiltsoglou I, Dimitriadou A, et al. Interleukin-4 suppresses antifungal activity of human mononuclear phagocytes against Candida albicans in association with decreased uptake of blastoconidia. FEMS Immunol Med Microbiol 1997; 19: 169-180.
28. Roilides E, Anastasiou-Katsiardani A, Dimitriadou-Georgiadou A, et al. Suppressive effects of interleukin-10 on human mononuclear phagocyte function against Candida albicans and Staphylococcus aureus. J Infect Dis 1998; 178: 1734-1742.
29. Roilides E, Katsifa H, Tsaparidou S, et al. Interleukin-10 suppresses phagocytic and antihyphal activities of human neutrophils. Cytokine 2000; 12: 379-387.
30. Romani L. Cytokine modulation of specific and nonspecific immunity to Candida albicans. Mycoses 1999; 42: 45-48.
31. Donahue RE, Seehra J, Metzger M, et al. Human IL-3 and GM-CSF act synergistically in stimulating hematopoiesis in primates. Science 1988; 241: 1820-1823.
32. Mayer P, Lam C, Obenaus H, Liehl E, Besemer J. Recombinant human GM-CSF induces leukocytosis and activates peripheral blood polymorphonuclear neutrophils in nonhuman primates. Blood 1987; 70: 206-213.
33. Mayer P, Schutze C, Lam C, Kricek F, Liehl E. Recombinant murine granulocyte-macrophage colony-stimulating factor augments neutrophil recovery and enhances resistance to infections in myelosuppressed mice. J Infect Dis 1991; 163: 584-590.
34. Kullberg BJ, Van Der Meer JW, Meis JF, et al. Recombinant murine granulocyte colony-stimulating factor protects against acute disseminated Candida albicans infection in nonneutropenic mice. J Infect Dis 1998; 177: 175-181.
35. Graybill JR, Bocanerga R, Luther M. Antifungal combination with G-CSF and fluconazole in experimental disseminated candidiasis. Eur J Clin Microbiol Infect Dis 1995; 14: 700-703.
36. Polak-Wyss A. Protective effect of human granulocyte colony-stimulating factor on Candida infections in normal and immunosuppressed mice. Mycoses 1991; 34: 109-118.
37. Hamood M, Bluche PF, De Vroey C, et al. Effects of rhG-CSF on neutropenic mice infected with C. albicans: Acceleration of recovery from neutropenia and potentiation of anti-Candida resistance. Mycoses 1994; 37: 93-99.
38. Uchida K, Yamamoto Y, Klein TW, Friedman H, Yamaguchi H. Granulocyte-colony stimulating factor facilitates the restoration of resistance to opportunistic fungi in leukopenic mice. J Med Vet Mycol 1992; 30: 293-300.
39. Vitt CR, Fidler JM, Ando D, Zimmerman RJ, Aukerman SL. Antifungal activity of rhM-CSF in models of acute and chronic candidiasis in the rat. J Infect Dis 1994; 169: 369-374.
40. Kuhara T, Uchida K, Yamaguchi H. Therapeutic efficacy of human macrophage colony-stimulating factor, used alone and in combination with antifungal agents, in mice with systemic Candida albicans infection. Antimicrob Agents Chemother 2000; 44: 19-23.
41. Kullberg BJ, Van't Wout JW, Hoogstraten C, Van Furth R. Recombinant interferon-g enhances resistance to acute disseminated Candida albicans infection in mice. J Infect Dis 1993; 168: 436-443.
42. Van't Wout JW, Van Der Meer JWM, Barza M, Dinarello CA. Protection of neutropenic mice from lethal Candida albicans infection by recombinant interleukin 1. Eur J Immunol 1988; 18: 1143-1146.
43. Kullberg BJ, Van't Wout JW, Poell RJ, Van Furth R. Combined effect of fluconazole and recombinant human interleukin-1 on systemic candidiasis in neutropenic mice. Antimicrob Agents Chemother 1992; 36: 1225-1229.
44. Tonnetti L, Spaccapelo R, Cenci E, et al. Interleukin-4 and -10 exacerbate candidiasis in mice. Eur J Immunol 1995; 25: 1559-1565.
45. Romani L, Puccetti P, Mencacci A, et al. Neutralization of IL-10 upregulates nitric oxide production and protects susceptible mice from challenge with Candida albicans. J Immunol 1994; 152: 3514-3521.
46. Del Sero G, Mencacci A, Cenci E, et al. Antifungal type 1 responses are upregulated in IL-10-deficient mice. Microbes Infect 1999; 1: 1169-1180.
47. Antman KS, Griffin JD, Elias A, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 1988; 319: 593-598.
48. Lieschke GJ, Maher D, Cebon J, et al. Effects of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy. Ann Intern Med 1989; 110: 357-364.
49. Nemunaitis J, Rabinowe S, Singer JW, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991; 324: 1773-1778.
50. Link H, Boogaerts MA, Carella AM, et al. A controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor after total body irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma. Blood 1992; 80: 2188-2195.
51. Anaissie EJ, Vartivarian S, Bodey GP, et al. Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia. Am J Med 1996; 100: 17-23.
52. Buchner T, Hiddemann W, Koenigsmann M, et al. Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 1991; 78: 1190-1197.
53. De Witte T, Gratwohl A, Van Der Lely N, et al. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell-depleted bone marrow transplantation. Blood 1992; 79: 1359-1365.
54. Löwenberg B, Suciu S, Archimbaud E, et al. Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): Final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organization for the Research and Treatment of Cancer (EORTC-LCG) and the Dutch Belgian Hematol-Oncology Cooperative Group (HOVON). Blood 1997; 90: 2952-2961.
55. Stone RM, Berg DB, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 1995; 332: 1671-1677.
56. Jones TC. Use of granulocyte-macrophage colony stimulating factor (GM-CSF) in prevention and treatment of fungal infections. Eur J Cancer 1999; 35: S8-10.
57. Mangi MH, Newland AC. Febrile neutropenia: Prophylactic and therapeutic use of GM-CSF. Eur J Cancer 1999; 35: S4-7.
58. Lopez AF, Williamson DJ, Gamble JR, et al. Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival. J Clin Invest 1986; 78: 1220-1228.
59. Berenguer J, Buck M, Witebsky F, et al. Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection. Diagn Microbiol Infect Dis 1993; 17: 103-109.
60. Nemunaitis J, Buckner CD, Dorsey KS, et al. Retrospective analysis of infectious disease in patients who received recombinant human granulocyte-macrophage colony-stimulating factor versus patients not receiving a cytokine who underwent autologous bone marrow transplantation for treatment of lymphoid cancer. Am J Clin Oncol 1998; 21: 341-346.
61. Peters BG, Adkins DR, Harrison B, et al. Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: A retrospective analysis. Bone Marrow Transplant 1996; 18: 93-102.
62. Bodey GP, Anaissie E, Gutterman J, Vadhan Raj S. Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer. Clin Infect Dis 1993; 17: 705-707.
63. Maertens J, Demuynck H, Verhoef G, et al. GM-CSF fails to improve outcome in invasive fungal infections in neutropenic cancer patients. (Abstr. 560). In: 13th Congress of the Intern Soc Hum Animal Mycol; 1997; Parma Italy; 1997.
64. Nemunaitis J, Shannon-Dorcy K, Appelbaum FR, et al. Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor. Blood 1993; 82: 1422-1427.
65. Erduran E, Yildiran A, Gedik Y. Multiple fungal brain abscesses in a child with acute myeloblastic leukemia. Pediatr Hematol Oncol 1998; 15: 463-466.
66. Poynton CH, Barnes RA, Rees J. Interferon gamma and granulocyte-macrophage colony-stimulating factor for the treatment of hepatosplenic candidosis in patients with acute leukemia. Clin Infect Dis 1998; 26: 239-240.
67. Rowe JM, Anderson JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years) with acute myelogenous leukemia: A study by the Eastern Cooperative Oncology Group (E1490). Blood 1995; 86: 457-462.
68. Rowe JM. Treatment of acute myeloid leukemia with cytokines: Effect on duration of neutropenia and response to infections. Clin Infect Dis 1998; 26: 1290-1294.
69. Champlin RE, Nimer SD, Ireland P, Oette DH, Golde DW. Treatment of refractory aplastic anemia with recombinant huma granulocyte -macrophage colony-stimulating factor. Blood 1989; 73: 694-699.
70. Vadhan-Raj S, Buescher S, Broxmeyer HE, et al. Stimulation of myelopoiesis in patients with aplastic anemia by recombinant huma granulocyte-macrophage colony-stimulating factor. N Engl J Med 1988; 319: 1628-1634.
71. Weinberger M, Elattar I, Marshall D, et al. Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death. Medicine (Baltimore) 1992; 71: 24-43.
72. Suri M, Harrison L, Van De Ven C, Cairo MS. Immunotherapy in the prophylaxis and treatment of neonatal sepsis. Curr Opin Pediatr 2003; 15: 155-160.
73. Miura E, Procianoy RS, Bittar C, et al. A randomized, double-masked, placebo-controlled trial of recombinant granulocyte colony-stimulating factor administration to preterm infants with the clinical diagnosis of early-onset sepsis. Pediatrics 2001; 107: 30-35.
74. Bilgin K, Yaramis A, Haspolat K, et al. A randomized trial of granulocyte-macrophage colony-stimulating factor in neonates with sepsis and neutropenia. Pediatrics 2001; 107: 36-41.
75. Sreenan C, Osiovich H. Myeloid colony-stimulating factors: Use in the newborn. Arch Pediatr Adolesc Med 1999; 153: 984-988.
76. Souza LM, Boone TC, Gabrilove J, et al. Recombinant human granulocyte colony-stimulating factor. Science 1986; 232: 61-65.
77. Kitagawa S, You A, Souza LM, et al. Recombinant human granulocyte colony-stimulating factor enhances superoxide release in human granulocytes stimulated by chemotactic peptide. Biochem Biophys Res Commun 1987; 144: 1143-1146.
78. Gillio AP, Bonilla MA, Potter GK, et al. Effects of recombinant human granulocyte colony-stimulating factor on hemotopoietic reconstitution after autologous bone marrow transplantation in primates. Transplant Proc 1987; 19: 153-156.
79. Mizushima Y, Morikage T, Kuwahara T, Yano S. Effects of granulocyte colony-stimulating factor on hematopoietic injury induced by anticancer drugs in mice. J Biol Res Modifiers 1990; 9: 576-583.
80. Welte K, Bonilla MA, Gillio AP, et al. Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates. J Exp Med 1987; 165: 941-948.
81. Matsumoto M, Matsubara S, Matsuno T, et al. Protective effect of human granulocyte colony-stimulating factor on microbial infection in neutropenic mice. Infect Immun 1987; 55: 2715-2720.
82. Kullberg BJ, Netea MG, Vonk AG, Van Der Meer JW. Modulation of neutrophil function in host defense against disseminated Candida albicans infection in mice. FEMS Immunol Med Microbiol 1999; 26: 299-307.
83. Gaviria JM, Van Burik JA, Dale DC, Root RK, Liles WC. Modulation of neutrophil-mediated activity against the pseudohyphal form of Candida albicans by granulocyte colony-stimulating factor (G-CSF) administered in vivo. J Infect Dis 1999; 179: 1301-1304.
84. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325: 164-170.
85. Ohno R, Tomonaga M, Kobayashi T, et al. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 1990; 323: 871-877.
86. Morstyn G, Campbell L, Souza LM, et al. Effect of granulocyte colony-stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1988; 1: 667-671.
87. Yoshida T, Nakamura S, Ohtake S, et al. Effect of granulocyte colony-stimulating factor on neutropenia due to chemotherapy for non-Hogdkin's lymphoma. Cancer 1990; 66: 1904-1909.
88. Bradstock K, Matthews J, Young G, et al. Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia. Leukemia 2001; 15: 1331-1338.
89. Maher DW, Lieschke GJ, Green M, et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med 1994; 121: 492-501.
90. Heil G, Hoelzer D, Sanz MA, et al. A randomized, double-blind, placebo-controlled, phase III study of Filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood 1997; 90: 4710-4718.
91. Ohno R, Miyawaki S, Hatake K, et al. Human urinary macrophage colony-stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia: A double-blind controlled study. J Clin Oncol 1997; 15: 2954-2965.
92. Nemunaitis J, Meyers JD, Buckner D, et al. Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections. Blood 1991; 78: 907-913.
93. Nemunaitis J. Use of macrophage colony-stimulating factor in the treatment of fungal infections. Clin Infect Dis 1998; 26: 1279-1281.
94. Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000; 18: 3558-3585.
95. Hughes WT, Armstrong D, Bodey GP, et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis 1997; 25: 551-573.
96. Ruthe RC, Andersen BR, Cunningham BL, Epstein RB. Efficacy of granulocyte transfusions in the control of systemic candidiasis in the leukopenic host. Blood 1978; 52: 493-498.
97. Strauss RG. Granulocyte transfusion therapy for hem/onc patients. Hem/Onc Ann 1994; 2: 304-309.
98. Vamvakas EC, Pineda AA. Determinants of the efficacy of prophylactic granulocyte transfusions: A meta-analysis. J Clin Apheresis 1997; 12: 74-81.
99. Chanock SJ, Gorlin JB. Granulocyte transfusions. Time for a second look. Infect Dis Clin North Am 1996; 10: 327-343.
100. Bhatia S, McCullough J, Perry EH, et al. Granulocyte transfusions: Efficacy in treating fungal infections in neutropenic patients following bone marrow transplantation. Transfusion 1994; 34: 226-232.
101. Dignani MC, Freireich EJ, Andersson BS, et al. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: A pilot study. Leukemia 1997; 11: 1621-1630.
102. Rex JH, Bhalla SC, Cohen DM, et al. Protection of human polymorphonuclear leukocyte function from the deleterious effects of isolation, irradiation, and storage by interferon-g and granulocyte colony-stimulating factor. Transfusion 1995; 35: 605-611.
103. Peters C, Minkov M, Matthes-Martin S, et al. Leucocyte transfusions from rhG-CSF or prednisolone stimulated donors for treatment of severe infections in immunocompromised neutropenic patients. Br J Haematol 1999; 106: 689-696.
104. Di Mario A, Sica S, Salutari P, et al. Granulocyte colony-stimulating factor-primed leukocyte transfusions in Candida tropicalis fungemia in neutropenic patients. Haematologica 1997; 82: 362-363.
105. Price TH, Bowden RA, Boeckh M, et al. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. Blood 2000; 95: 3302-3309.
106. Liles WC. Immunomodulatory approaches to augment phagocyte-mediated host defense for treatment of infectious diseases. Semin Respir Infect 2001; 16: 11-17.
107. Garner RE, Kuruganti U, Czarniecki CW, Chiu HH, Domer JE. In vivo immune responses to Candida albicans modified by treatment with recombinant murine gamma interferon. Infect Immun 1989; 57: 1800-1808.
108. Romani L, Mencacci A, Tonnetti L, Spaccapelo R, Cenci E, Puccetti P, et al. Interleukin-12 is both required and prognostic in vitro for T helper type 1 differentiation in murine candidiasis. J Immunol 1994; 152: 5167-5175.
109. Gaviria JM, Van Burik JA, Dale DC, Root RK, Liles WC. Comparison of interferon-gamma, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor for priming leukocyte-mediated hyphal damage of opportunistic fungal pathogens. J Infect Dis 1999; 179: 1038-1041.
110. Natarajan U, Brummer E, Stevens DA. Effect of granulocyte colony-stimulating factor on the candidacidal activity of polymorphonuclear neutrophils and their collaboration with fluconazole. Antimicrob Agents Chemother 1997; 41: 1575-1578.
111. Natarajan U, Randhawa N, Brummer E, Stevens DA. Effect of granulocyte-macrophage colony-stimulating factor on candidacidal activity of neutrophils, monocytes or monocyte-derived macrophages and synergy with fluconazole. J Med Microbiol 1998; 47: 359-363.
112. Vora S, Purimetla N, Brummer E, Stevens DA. Activity of voriconazole, a new triazole, combined with neutrophils or monocytes against Candida albicans: Effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Antimicrob Agents Chemother 1998; 42: 907-910.
113. Kullberg BJ, Van De Woude K, Aoun M, et al. A double-blind, randomized, placebo-controlled phase II study of filgrastim (recombinant granulocyte colony-stimulating factor) in combination with fluconazole for treatment of invasive candidiasis and candidemia in nonneutropenic patients (J-100). In: Program and Abstracts of the 38th Interscience Conference Antimicrob Agents Chemother; 1998; San Diego CA; 1998.
114. Stevens DA. Combination immunotherapy and antifungal chemotherapy. Clin Infect Dis 1998; 26: 1266-1269.
115. Stevens DA, Kullberg BJ, Brummer E, et al. Combined treatment: Antifungal drugs with antibodies, cytokines or drugs. Med Mycol 2000; 38: 305-315.
116. Puccetti P, Mencacci A, Cenci E, et al. Cure of murine candidiasis by recombinant soluble interleukin-4 receptor. J Infect Dis 1994; 169: 1325-1331.
117. Tanida T, Rao F, Hamada T, Ueta E, Osaki T. Lactoferrin peptide increases the survival of Candida albicans-inoculated mice by upregulating neutrophil and macrophage functions, especially in combination with amphotericin B and granulocyte-macrophage colony-stimulating factor. Infect Immun 2001; 69: 3883-3890.
118. Cenci E, Mencacci A, Spaccapelo R, et al. T helper cell type 1 (Th1)- and Th2-like responses are present in mice with gastric candidiasis but protective immunity is associated with Th1 development. J Infect Dis 1995; 171: 1279-1288.
119. Clemons KV, Stevens DA. Treatment of orogastrointestinal candidosis in SCID mice with fluconazole alone or in combination with recombinant granulocyte colony-stimulating factor or interferon-gamma. Med Mycol 2000; 38: 213-219.
120. Riddell LA, Pinching AJ, Hill S, et al. A phase III study of recombinant human interferon gamma to prevent opportunistic infections in advanced HIV disease. AIDS Res Hum Retroviruses 2001; 17: 789-797.